TG Therapeutics, Inc. (TGTX) stock
Close on Nov 11, 2026Market cap $10.07BP/E 99.6Yield –
TG Therapeutics, Inc. grew revenue 68.8% to $897.76M over the twelve months to Sep 30, 2026. Operating income rose 87.6% to $192.86M, moving the operating margin from 19.3% to 21.5%. Free cash flow was $85.56M. At the latest close the market valued the company at $10.07B, 99.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $10.07B
- P/E ratio
- 99.6
- Price to sales
- 11.21
- Price to book
- 17.59
- Dividend yield
- –
- Free cash flow yield
- 0.85%
Fundamentals
- Revenue
- $897.76M
- Net income
- $106.06M
- EPS, diluted
- $0.66
- Free cash flow
- $85.56M
- Book value per share
- $3.67
- Diluted shares
- 156M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $64.26
- Open
- $64.01
- Day's range
- $62.79 – $66.07
- Volume
- 2,059,538
- Average volume (20 days)
- 2,142,383
- Index membership
- S&P SmallCap 600 (since Nov 2024), Russell 2000, Russell 3000
- Beta (5 years)
- 1.71
- 52-week range
- $26.76 – $68.03
- RSI (14 days)
- 69.8
- Volatility (1 year)
- 46.0%
- Relative volume
- 1.03×
- WACC
- 12.8%
On 3 of our idea lists: Institutions accumulating, New highs on volume, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TGTX | S&P 500 | Difference | TGTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +18.8% | -2.4% | +21.2 pts | ||
| 3 months | +31.8% | -1.2% | +32.9 pts | ||
| Year to date | +120.6% | +12.3% | +108.3 pts | ||
| 1 year | +111.4% | +12.4% | +98.9 pts | ||
| 3 years | +543.4% | +78.8% | +464.6 pts | +86.0% | +21.4% |
| 5 years | +98.3% | +75.2% | +23.1 pts | +14.7% | +11.9% |
| 10 years | +1074.3% | +311.1% | +763.2 pts | +27.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TG Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
About TG Therapeutics
Pharmaceutical Preparations
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing targeted therapies for B-cell mediated conditions, primarily focusing on multiple sclerosis. Its lead commercial product is BRIUMVI (ublituximab-xiiy), an intravenously infused anti-CD20 monoclonal antibody approved to treat adult patients with relapsing forms of multiple sclerosis. The company also advances investigational candidates in its clinical pipeline, including a subcutaneous formulation of ublituximab and an allogeneic CAR T cell therapy known as azer-cel, while providing its therapeutic treatments directly to healthcare professionals and patients.
Company profile, executives and historyTG Therapeutics stock: common questions
What is TG Therapeutics's stock price?
TGTX closed at $65.76 on Nov 11, 2026, up 2.33% on the day. Over the past 52 weeks it traded between $26.76 and $68.03.
What is TG Therapeutics's market cap?
TG Therapeutics was worth $10.07B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TGTX's P/E ratio?
TGTX trades at 99.6 times earnings, based on diluted earnings per share of $0.66 over the twelve months to Sep 30, 2026.
How much revenue does TG Therapeutics make?
TG Therapeutics reported revenue of $897.76M for the twelve months to Sep 30, 2026, up 68.8% from a year earlier.
Does TG Therapeutics pay a dividend?
No. TG Therapeutics has not paid a cash dividend over the last twelve months.
When does TG Therapeutics report earnings next?
TG Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TGTX stock performed over the past year?
Including dividends, TGTX returned +111.4% over the past year, against +12.4% for the S&P 500.
How many TGTX shares are sold short?
29M shares were sold short at the latest FINRA report, 22.39% of the float, or 18.9 days of average trading volume.
Who are TG Therapeutics's competitors?
Companies most similar to TG Therapeutics by business, industry and size include RARE, IONS, TVTX, AXSM, LEGN.
See a number that looks wrong?